(S)-(2-acetamidomethyl)pyrrolidine | 345347-89-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (S)-(2-acetamidomethyl)pyrrolidine
• 英文别名: N-(S)-1-Pyrrolidin-2-ylmethyl-acetamide；N-[[(2S)-pyrrolidin-2-yl]methyl]acetamide
• CAS: 345347-89-9
• 化学式: C₇H₁₄N₂O
• 分子量: 142.201
• InChiKey: CVQWLGWRTGXOIE-ZETCQYMHSA-N

物化性质

• 沸点：
  314.3±15.0 °C(Predicted)
• 密度：
  0.982±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Novel succinate compounds, compositions and methods of use and preparation
  申请人：——

  公开号：US20020115863A1

  公开（公告）日：2002-08-22

  Novel hydroxamic acid compounds are disclosed. These hydroxamates inhibit peptidyl deformylase (PDF), an enzyme present in prokaryotes. The hydroxymates are useful as antimicrobials and antibiotics. The compounds of the invention display selective inhibition of peptidyl deformylase versus other metalloproteinases such as matrix metalloproteinases (MMPs). Methods of synthesis and of use of the compounds are also disclosed.

  揭示了一种新型羟羧酸化合物。这些羟羧酸酯抑制肽变形酶（PDF），这是一种存在于原核生物中的酶。这些羟羧酸酯可用作抗微生物和抗生素。该发明的化合物表现出对肽变形酶的选择性抑制，而不影响其他金属蛋白酶如基质金属蛋白酶（MMPs）。该文还揭示了这些化合物的合成方法和使用方法。
• [EN] OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY<br/>[FR] DÉRIVÉS D'OXYINDOLE AYANT UNE ACTIVITÉ AGONISTE AU RÉCEPTEUR DE LA MOTILINE
  申请人：RAQUALIA PHARMA INC

  公开号：WO2010098145A1

  公开（公告）日：2010-09-02

  The present invention relates to novel oxyindole derivatives of formula (I) or a pharmaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the motilin receptor (GPR38).

  本发明涉及公式（I）的新型氧吲哚衍生物或其药用盐，其制备方法，包含它们的药物组合物以及它们在治疗通过胃动素受体（GPR38）介导的各种疾病中的用途。
• [EN] NOVEL SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION<br/>[FR] NOUVEAUX COMPOSES A BASE DE SUCCINATE, COMPOSITIONS LES CONTENANT, ET PROCEDES D'UTILISATION ET DE PREPARATION DE CEUX-CI
  申请人：VERSICOR INC

  公开号：WO2001044179A1

  公开（公告）日：2001-06-21

  Novel hydroxamic acid compounds of Formula (I) are disclosed. These hydroxamates inhibit peptide deformylase (PDF), an enzyme present in prokaryotes. The hydroxymates are useful as antimicrobials and antibiotics. The compounds of the invention display selective inhibition of peptidyl deformylase versus other metalloproteinases such as matrix metalloproteinases (MMPs). Methods of synthesis and of use of the compounds are also disclosed.

  本发明揭示了式（I）的新型羟肟酸化合物。这些羟肟酸盐抑制肽变形酶（PDF），一种存在于原核生物中的酶。这些羟肟酸盐可用作抗微生物和抗生素。本发明的化合物显示出对肽酰变形酶的选择性抑制，而不是其他金属蛋白酶如基质金属蛋白酶（MMPs）。本发明还揭示了这些化合物的合成和使用方法。
• Organocatalysts and Methods of Use in Chemical Synthesis
  申请人：Wang Wie

  公开号：US20070244328A1

  公开（公告）日：2007-10-18

  The present invention pertains generally to compositions comprising organocatalysts that facilitate stereo-selective reactions and the method of their synthesis and use. Particularly, the invention relates to metal-free organocatalysts for facilitation of stereo-selective reactions, and the method of their synthesis and use. These compounds have the structure of the Formulas (I) and (II). Where X is independently selected from CH 2 , N—R a , O, S or C═O; Y is CH 2 , N—R a , O, S or C═O, with the proviso that at least one of X or Y is CH 2 , and preferably both of X and Y are CH 2 ; R a is H, an optionally substituted C 1 -C 12 alkyl, preferably an optionally substituted C 1 -C 6 alkyl including a C 3 -C 6 cyclic alkyl group, or an optionally substituted aryl group, preferably an optionally substituted phenyl group; R b is H, an optionally substituted C 1 -C 12 alkyl, preferably an optionally substituted C 1 -C 6 acyclic or a a C 3 -C 6 cyclic alkyl group, CIIO, N(Me)O, CO(S)R a or the group of Formula (III). Where R c and R d are each independently H, F, Cl, an optionally substituted C 1 -C 20 alkyl, preferably an optionally substituted C 1 -C 12 alkyl, more preferably a C 1 -C 6 alkyl, and an optionally substituted aryl group, or together R c and R d form an optionally substituted carbocyclic or optionally substituted heterocyclic ring; R 1 is OH, OR, NR′R″, NHC(═O)R, NHSO 2 R; R 2 is H, F, Cl, an optionally substituted C 1 -C 20 alkyl, preferably an optionally substituted C 1 C 6 alkyl, an optionally substituted aryl group or a ═O group (which establishes a carbonyl group with the carbon to which ═O is attached; R 3 is H, OH, F, Cl, Br, I, Cl, an optionally substituted C 1 -C 20 alkyl, alkenyl or alkynyl (“hydrocarbyl”) group, preferably an optionally substituted C 1 -C 6 alkyl, or an optionally substituted aryl, such that the carbon to which R 3 is attached has an R or S configuration; R is II, an optionally substituted C 1 -C 20 alkyl, preferably an optionally substituted C 1 -C 6 alkyl, or an optionally substituted aryl group, R′ and R″ are each independently H, an optionally substituted C 1 -C 20 alkyl group, preferably an optionally substituted C 1 -C 6 alkyl, or an optionally substituted aryl group; or together R′ and R″ form an optionally substituted heterocyclic, preferably a 4 to 7 membered optionally substituted heterocyclic group or an optionally substituted heteroaryl ring with the nitrogen to which R′ and R″ are attached; and wherein said compound is free from a metal catalyst.

  本发明涉及一种包含有机催化剂的组合物，该组合物促进立体选择性反应及其合成和使用的方法。特别地，本发明涉及无金属有机催化剂，以促进立体选择性反应，以及其合成和使用的方法。这些化合物具有公式（I）和（II）的结构。其中，X独立地选自CH2、N—Ra、O、S或C═O；Y为 、N—Ra、O、S或C═O，但至少X或Y中的一个为 ，最好是X和Y都为 ；Ra为H、可选取代的C1-C12烷基，最好是可选取代的C1-C6烷基，包括C3-C6环烷基，或可选取代的芳基，最好是可选取代的苯基；Rb为H、可选取代的C1-C12烷基，最好是可选取代的C1-C6非环烷基或C3-C6环烷基，CIIO、N(Me)O、CO(S)Ra或公式（III）的基团。其中，Rc和Rd各自独立地为H、F、Cl、可选取代的C1-C20烷基，最好是可选取代的C1-C12烷基，更好是C1-C6烷基，以及可选取代的芳基，或者Rc和Rd一起形成可选取代的碳环或可选取代的杂环；R1为OH、OR、NR′R″、NHC(═O)R、NHSO2R；R2为H、F、Cl、可选取代的C1-C20烷基，最好是可选取代的C1-C6烷基、可选取代的芳基或═O基团（与═O相连的碳原子上形成羰基基团）；R3为H、OH、F、Cl、Br、I、Cl、可选取代的C1-C20烷基、烯基或炔基（“烃基”）团，最好是可选取代的C1-C6烷基，或可选取代的芳基，使得R3连接的碳原子具有R或S构型；R为II、可选取代的C1-C20烷基，最好是可选取代的C1-C6烷基，或可选取代的芳基团，R′和R″各自独立地为H、可选取代的C1-C20烷基团，最好是可选取代的C1-C6烷基，或可选取代的芳基团；或者R′和R″一起形成可选取代的杂环，最好是4到7个成员的可选取代的杂环基团或与R′和R″连接的氮原子一起形成可选取代的杂环芳基环；其中所述化合物不含金属催化剂。
• INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF
  申请人：Nanjing Transthera Biosciences Co. Ltd.

  公开号：EP3508482A1

  公开（公告）日：2019-07-10

  Provided are an irreversible inhibitor of a fibroblast growth factor receptor (FGFR) as indicated by formula I, a pharmaceutically acceptable salt, a stereoisomer, a pharmaceutical preparation, a pharmaceutical composition and an application thereof. R1, R2, R3, R4, ring A, Ar, ring B and warhead are as defined in the specification. The compound has high-efficiency and high-selectivity inhibition of a fibroblast growth factor receptor and can be applied to treatment of abnormal FGF/FGFR-mediated diseases, in particular the treatment of cancers.

  本发明提供了一种如式 I 所示的成纤维细胞生长因子受体（FGFR）不可逆抑制剂、一种药学上可接受的盐、一种立体异构体、一种药物制剂、一种药物组合物及其应用。R1、R2、R3、R4、环 A、Ar、环 B 和弹头如说明书中所定义。该化合物对成纤维细胞生长因子受体具有高效率和高选择性的抑制作用，可应用于治疗异常的FGF/FGFR介导的疾病，特别是癌症的治疗。